 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Edwards Lifesciences Corporation (EW) provides products and technologies to treat structural heart disease and critically ill patients worldwide.
It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves.
The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patients diseased or defective heart valve. In addition, it produces pericardial valves from biologically inert animal tissue; and provides heart valve repair therapies, including annuloplasty rings and systems.
Further, the company offers critical care products, such as hemodynamic monitoring systems to measure a patients heart function in surgical and intensive care settings; pulmonary artery catheters; and continuous venous oximetry catheter for measuring central venous oxygen saturation.
Additionally, its critical care products include disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection; and peripheral vascular products used to treat endolumenal occlusive disease, such as embolectomy catheters for removing blood clots from peripheral blood vessels. The company distributes its products through direct sales force and independent distributors.
Shares have formed a bullish "flag" after several positive developments for the firm. Furthermore, the firm reported strong results yesterday and guided higher going forward. It reported EPS of 77 cents above the expected 66 cents. It now expects full-year earnings of $2.67 to $2.77 a share, which is 10 cents above the outlook it gave in February. It raised its outlook for full-year net sales to a range of $2.7 billion to $3 billion from its previous forecast of $2.6 billion to $2.85 billion. Higher share prices are expected for this stock.
52-Weeks Trading Range: $61.38 - $112.00
Entry Point: $110.00
Stop Loss: $104.50
Target Price: $121.00
EW closed at $101.06.
